{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:37:39Z","timestamp":1771007859356,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00280-021-04330-1","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T15:03:09Z","timestamp":1627311789000},"page":"813-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-1848","authenticated-orcid":false,"given":"Goretti","family":"Duran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Agu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Gir\u00e1ldez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Bern\u00e1rdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Zarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Carracedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"6","key":"4330_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay JSI, Soerjomataram I et al (2018) Global cancer statistic 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"4330_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941\u20131953","journal-title":"Int J Cancer"},{"issue":"1","key":"4330_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4\u201314","journal-title":"Radiother Oncol"},{"issue":"5","key":"4330_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/ijgc-00009577-200309000-00016","volume":"13","author":"MC Terek","year":"2003","unstructured":"Terek MC, Zekioglu O, Sendag F, Akercan F, Ozsaran A, Erhan Y (2003) MDR1 gene expression in endometrial carcinoma. Int J Gynecol Cancer 13(5):673\u2013677","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"4330_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1677\/erc.0.0100043","volume":"10","author":"F Leonessa","year":"2003","unstructured":"Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10(1):43\u201373","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"4330_CR6","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/carcin\/21.11.1977","volume":"21","author":"BN Ford","year":"2000","unstructured":"Ford BN, Ruttan CC, Kyle VL, Brackley ME, Glickman BW (2000) Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis 21(11):1977\u20131981","journal-title":"Carcinogenesis"},{"issue":"12","key":"4330_CR7","first-page":"1513","volume":"11","author":"EL Goode","year":"2002","unstructured":"Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12):1513\u20131530","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"4330_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6601729","volume":"90","author":"H Willers","year":"2004","unstructured":"Willers H, Dahm-Daphi J, Powell SN (2004) Repair of radiation damage to DNA. Br J Cancer 90(7):1297\u20131301","journal-title":"Br J Cancer"},{"issue":"4","key":"4330_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.semradonc.2010.05.003","volume":"20","author":"MB Parliament","year":"2010","unstructured":"Parliament MB, Murray D (2010) Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol 20(4):232\u2013240","journal-title":"Semin Radiat Oncol"},{"issue":"8","key":"4330_CR10","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/hed.25754","volume":"41","author":"G Duran","year":"2019","unstructured":"Duran G, Aguin S, Cruz R, Barros F, Giraldez JM, Bernardez B et al (2019) Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment. Head Neck 41(8):2704\u20132715","journal-title":"Head Neck"},{"issue":"2","key":"4330_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jtbi.2005.11.036","volume":"241","author":"JH Moore","year":"2006","unstructured":"Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N et al (2006) A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241(2):252\u2013261","journal-title":"J Theor Biol"},{"issue":"2","key":"4330_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.lungcan.2010.09.001","volume":"72","author":"B Han","year":"2011","unstructured":"Han B, Gao G, Wu W, Gao Z, Zhao X, Li L et al (2011) Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 72(2):238\u2013243","journal-title":"Lung Cancer"},{"issue":"12","key":"4330_CR13","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1002\/ijc.27567","volume":"131","author":"D Campa","year":"2012","unstructured":"Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP et al (2012) A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131(12):2920\u20132928","journal-title":"Int J Cancer"},{"issue":"5","key":"4330_CR14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.arcmed.2011.07.008","volume":"42","author":"HB Wei","year":"2011","unstructured":"Wei HB, Lu XS, Shang LH, Xu G, Hu J, Che DH et al (2011) Polymorphisms of ERCC1 C118T\/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 42(5):412\u2013420","journal-title":"Arch Med Res"},{"issue":"6","key":"4330_CR15","doi-asserted-by":"publisher","first-page":"e38150","DOI":"10.1371\/journal.pone.0038150","volume":"7","author":"JY Yin","year":"2012","unstructured":"Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7(6):e38150","journal-title":"PLoS ONE"},{"issue":"4","key":"4330_CR16","doi-asserted-by":"publisher","first-page":"e62023","DOI":"10.1371\/journal.pone.0062023","volume":"8","author":"C Zhang","year":"2013","unstructured":"Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G et al (2013) Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS ONE 8(4):e62023","journal-title":"PLoS ONE"},{"issue":"3","key":"4330_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5604\/00306657.1202546","volume":"70","author":"W Pietruszewska","year":"2016","unstructured":"Pietruszewska W, Bojanowska-Pozniak K, Kobos J (2016) Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study. Otolaryngol Pol 70(3):32\u201343","journal-title":"Otolaryngol Pol"},{"issue":"14","key":"4330_CR18","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1002\/cncr.26669","volume":"118","author":"X Zhao","year":"2012","unstructured":"Zhao X, Wang X, Wu W, Gao Z, Wu J, Garfield DH et al (2012) Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy. Cancer 118(14):3587\u20133598","journal-title":"Cancer"},{"key":"4330_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1471-2407-12-121","volume":"12","author":"P Gonzalez-Arriaga","year":"2012","unstructured":"Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A (2012) Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12:121","journal-title":"BMC Cancer"},{"issue":"4","key":"4330_CR20","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","volume":"35","author":"Y Yang","year":"2014","unstructured":"Yang Y, Xian L (2014) The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35(4):2905\u20132921","journal-title":"Tumour Biol"},{"issue":"3","key":"4330_CR21","doi-asserted-by":"publisher","first-page":"e33200","DOI":"10.1371\/journal.pone.0033200","volume":"7","author":"W Wu","year":"2012","unstructured":"Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R et al (2012) Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS ONE 7(3):e33200","journal-title":"PLoS ONE"},{"issue":"26","key":"4330_CR22","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2006.05.8768","volume":"24","author":"M Quintela-Fandino","year":"2006","unstructured":"Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H et al (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24(26):4333\u20134339","journal-title":"J Clin Oncol"},{"issue":"24","key":"4330_CR23","first-page":"8654","volume":"61","author":"DJ Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61(24):8654\u20138658","journal-title":"Cancer Res"},{"issue":"6","key":"4330_CR24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","volume":"14","author":"C Tibaldi","year":"2008","unstructured":"Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14(6):1797\u20131803","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4330_CR25","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.4238\/2014.April.29.9","volume":"13","author":"M Zhou","year":"2014","unstructured":"Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y, Wan HY (2014) Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genet Mol Res 13(2):3310\u20133318","journal-title":"Genet Mol Res"},{"issue":"3","key":"4330_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","volume":"44","author":"JS Ryu","year":"2004","unstructured":"Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM et al (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3):311\u2013316","journal-title":"Lung Cancer"},{"issue":"39","key":"4330_CR27","doi-asserted-by":"publisher","first-page":"e1593","DOI":"10.1097\/MD.0000000000001593","volume":"94","author":"M Qixing","year":"2015","unstructured":"Qixing M, Gaochao D, Wenjie X, Rong Y, Feng J, Lin X et al (2015) Predictive value of Ercc1 and Xpd polymorphisms for clinical outcomes of patients receiving neoadjuvant therapy: a prisma-compliant meta-analysis. Medicine (Baltimore) 94(39):e1593","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4330_CR28","first-page":"2934","volume":"8","author":"J Lu","year":"2015","unstructured":"Lu J, Zhao H, Li S, Tian Z, Zhu X, Wang H et al (2015) Correlation of rs1799793 polymorphism in ERCC2 and the clinical response to platinum-based chemotherapy in patients with triple negative breast cancer. Int J Clin Exp Med 8(2):2934\u20132938","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"4330_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00280-016-3015-9","volume":"77","author":"F Li","year":"2016","unstructured":"Li F, Xie X, Ren X, Zhang J (2016) A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother Pharmacol 77(6):1183\u20131191","journal-title":"Cancer Chemother Pharmacol"},{"key":"4330_CR30","doi-asserted-by":"crossref","unstructured":"Bi\u0161of V, Zajc Petranovi\u0107 M, Raku\u0161i\u0107 Z, Samard\u017ei\u0107 KR, Jureti\u0107 A (2016) The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. Eur Arch Otorhinolaryngol 273(9):2305\u20132317","DOI":"10.1007\/s00405-015-3710-x"},{"issue":"7","key":"4330_CR31","first-page":"2286","volume":"8","author":"RV Lord","year":"2002","unstructured":"Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8(7):2286\u20132291","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4330_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","volume":"16","author":"R Metzger","year":"1998","unstructured":"Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16(1):309\u2013316","journal-title":"J Clin Oncol"},{"issue":"15","key":"4330_CR33","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1158\/1078-0432.CCR-12-2792","volume":"19","author":"HS Jeon","year":"2013","unstructured":"Jeon HS, Jin G, Kang HG, Choi YY, Lee WK, Choi JE et al (2013) A functional variant at 19q13.3, rs967591G>A, is associated with shorter survival of early-stage lung cancer. Clin Cancer Res 19(15):4185\u20134195","journal-title":"Clin Cancer Res"},{"key":"4330_CR34","first-page":"47","volume":"4","author":"A Vaezi","year":"2011","unstructured":"Vaezi A, Feldman CH, Niedernhofer LJ (2011) ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmgenomics Pers Med 4:47\u201363","journal-title":"Pharmgenomics Pers Med"},{"issue":"8","key":"4330_CR35","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1007\/s13277-014-2072-0","volume":"35","author":"XP Li","year":"2014","unstructured":"Li XP, Yin JY, Wang Y, He H, Li X, Gong WJ et al (2014) The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol 35(8):8259\u20138265","journal-title":"Tumour Biol"},{"key":"4330_CR36","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1038\/cddis.2014.10","volume":"5","author":"RC Turkington","year":"2014","unstructured":"Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD et al (2014) Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis 5:e1046","journal-title":"Cell Death Dis"},{"issue":"2","key":"4330_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ijc.20204","volume":"111","author":"S Streit","year":"2004","unstructured":"Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111(2):213\u2013217","journal-title":"Int J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04330-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T13:31:49Z","timestamp":1699277509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04330-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}